UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                             Washington, DC 20549


                                  FORM 10-QSB



[X]   Quarterly Report pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934

      For the quarterly period ended  November 30, 2005
                                      -----------------

[ ]   Transition Report pursuant to 13 or 15(d) of the Securities Exchange
      Act of 1934

      For the transition period                  to
                               ------------------   --------------------

      Commission File Number    333-107179
                            -----------------


                             XPENTION GENETICS, INC.
    ------------------------------------------------------------------------
       (Exact name of small Business Issuer as specified in its charter)


                               BAYVIEW CORPORATION
    ------------------------------------------------------------------------
     (Former name, former address and former fiscal year, if changed since
                                 last report)



          Nevada                                         98-0380519
---------------------------------             --------------------------------
(State or other jurisdiction of              (IRS Employer Identification No.)
 incorporation or organization)

10965 Elizabeth Drive
Conifer, CO                                               80433
----------------------------------------      --------------------------------
(Address of principal executive offices)           (Postal or Zip Code)


Issuer's telephone number, including area code:        (303) 908-4900
                                                ------------------------------


Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the issuer was required to file such
reports), and (2) has been subject to such filing requirements for the past 90
days [X] Yes [ ] No

State the number of shares outstanding of each of the issuer's classes of common
stock, as of the latest practicable date:  57,625,833 shares of $0.001 par value
common stock outstanding as of January 23, 2006.




<PAGE>

                          PART I FINANCIAL INFORMATION

Item 1.  Financial Statements


                             XPENTION GENETICS, INC.
                          (A Development Stage Company)



                                NOVEMBER 30, 2005
                                   (Unaudited)


<PAGE>

                             XPENTION GENETICS, INC.
                          (A Development Stage Company)
                           Consolidated Balance Sheet
                                November 30, 2005
                                   (Unaudited)

ASSETS

Current assets
Cash and cash equivalents                                             $ 178,709
                                                                      ==========

LIABILITIES

Current liabilities
Accounts payable                                                       $     60
Accrued expenses                                                        104,651
   Note payable                                                         100,000
                                                                       ---------
    Total current liabilities                                           204,711
                                                                       ---------

STOCKHOLDERS' (DEFICIT)

Preferred stock, $0.001 par value, 10,000,000 shares authorized,
  none issued or outstanding                                                  -
Common stock, $0.001 par value, 100,000,000 shares authorized,
  57,625,833 shares issued and outstanding                               57,625
Additional paid-in capital                                              795,475
Deferred stock compensation                                            (184,500)
   (Deficit) accumulated during the development stage                  (696,719)
Other comprehensive income:
  Currency translation gain                                               2,117
                                                                      ----------
                                                                        (26,002)
                                                                      ----------
                                                                      $ 178,709
                                                                      ==========


 The accompanying footnotes are an integral part of these financial statements.

                                      F-1

<PAGE>

<TABLE>
<CAPTION>

                                     XPENTION GENETICS, INC.
                                  (A Development Stage Company)
                 CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
                   THREE AND SIX MONTHS ENDED NOVEMBER 30, 2005 AND 2004, AND
                       (INCEPTION) SEPTEMBER 5, 2002 TO NOVEMBER 30, 2005
                                           (Unaudited)



                                                                                                          (Inception)
                                     Three Months Ended November 30,  Six Months Ended November 30,    September 5, 2002
                                          2005            2004             2005             2004      to November 30, 2005
                                     -------------   -------------    -------------    --------------  -------------------
<S>                                  <C>             <C>              <C>              <C>             <C>
Revenues                              $         -    $          -     $          -     $           -   $                -
                                     -------------   -------------    -------------    --------------  -------------------
Expenses
   Purchased research and development           -               -                -                 -              109,891
   Research and development               102,665               -          181,425                 -              181,425
   Stock compensation                      92,250               -          184,500                 -              184,500
     General and administrative            30,828           2,864           85,427             3,860              186,378
     Mineral property exploration               -               -                -                 -               19,100
     Mineral property option payments           -           2,000                -             2,000               11,500
                                     -------------   -------------    -------------    --------------  -------------------
                                          225,743           4,864          451,352             5,860              692,794
                                     -------------   -------------    -------------    --------------  -------------------
Operating (loss)                         (225,743)         (4,864)        (451,352)           (5,860)            (692,794)
                                     -------------   -------------    -------------    --------------  -------------------
Other income (expense)
  Interest expense                         (1,250)              -           (2,500)                -               (3,925)
                                     -------------   -------------    -------------    --------------  -------------------
Net (loss)                               (226,993)         (4,864)        (453,852)           (5,860)            (696,719)
                                     -------------   -------------    -------------    --------------  -------------------
Comprehensive income:
  Currency translation gain                     -               -                -                 -                2,117

Comprehensive (loss)                  $  (226,993)    $    (4,864)    $   (453,852)     $     (5,860)   $        (694,602)
                                     =============   =============    =============    ==============  ===================

Weighted average shares outstanding    57,625,833       42,542,500       57,529,658       42,542,500
                                     =============   =============    =============    ==============

Basic and diluted:
  (Loss) per share                    $     (0.00)   $      (0.00)    $      (0.01)    $       (0.00)
                                     =============   =============    =============    ==============



         The accompanying footnotes are an integral part of these financial statements.


                                              F-2
</TABLE>

<PAGE>

<TABLE>
<CAPTION>

                                     XPENTION GENETICS, INC.
                                  (A Development Stage Company)
                              CONSOLIDATED STATEMENTS OF CASH FLOWS
                        SIX MONTHS ENDED NOVEMBER 30, 2005 AND 2004, AND
                       (INCEPTION) SEPTEMBER 5, 2002 TO NOVEMBER 30, 2005
                                           (Unaudited)

                                                                                                  (Inception)
                                                             Six Months Ended November 30,      September 5, 2002
                                                                2005         2004              to November 30, 2005
                                                         ----------------    ----------------   ------------------
<S>                                                      <C>                 <C>                <C>
Cash Flows From Operating Activities
  Net (loss)                                             $      (453,852)    $        (5,860)    $       (696,719)
Adjustments to reconcile net (loss) to net cash (used
  in) operating activities
      Purchased research and development                               -                   -              109,891
      Stock compensation expense                                 184,500                   -              184,500
      Foreign currency translation                                     -                   -                2,117
      Prepaid expenses                                                 -                   -               15,000
      Accounts payable and accrued liabilities                    32,639               3,796               66,123
                                                         ----------------    ----------------   ------------------
Cash flows (used in) operating activities                       (236,713)             (2,064)            (319,088)
                                                         ----------------    ----------------   ------------------

Cash Flows From Investing Activities
  Cash received in Xpention acquisition                                -                   -               19,297
                                                         ----------------    ----------------   ------------------
Cash flows provided by investing activities                            -                   -               19,297
                                                         ----------------    ----------------   ------------------

Cash Flows From Financing Activities
  Proceeds from issuance of common stock                         400,000                   -              478,500
                                                         ----------------    ----------------   ------------------
Cash flows provided by financing activities                      400,000                   -              478,500
                                                         ----------------    ----------------   ------------------
Increase (decrease) in cash                                      163,287              (2,064)             178,709

Cash, beginning of period                                         15,422              27,246                    -
                                                         ----------------    ----------------   ------------------
Cash, end of period                                      $       178,709     $        25,182     $        178,709
                                                         ================    ================   ==================



 The accompanying footnotes are an integral part of these financial statements.

                                      F-3
</TABLE>


<PAGE>

<TABLE>
<CAPTION>

                                     XPENTION GENETICS, INC.
                                  (A Development Stage Company)
                    CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)
                       INCEPTION (SEPTEMBER 5, 2002) TO NOVEMBER 30, 2005
                                          (Unaudited)

                                                                                           (Deficit)
                                                                               Deferred    Accumulated
                                           Common Stock        Additional       Stock      During the     Comprehensive
                                         Shares     Amount   Paid in Capital Compensation  Development       Income         Total
                                       ------------------------------------------------------------------------------------------
<S>                                     <C>          <C>          <C>           <C>          <C>           <C>           <C>
Inception (September 5, 2002)                    -    $    -          $  -          $  -            $-        $  -       $     -

October 2002, shares issued for
  cash at $0.000077                     13,000,000     1,000             -             -             -           -         1,000

November 2002, shares issued for
  cash at $0.00077                      26,000,000    20,000             -             -             -           -        20,000

January 2003, shares issued for
  cash at $0.015                         3,412,500     3,412        49,088             -             -           -        52,500

Reclassification of paid in capital              -    18,000       (18,000)            -             -           -             -

February 2003, shares issued for
  cash at $0.0385                          130,000       130         4,870             -             -           -         5,000

Net (loss)                                       -         -             -             -       (24,312)          -       (24,312)
                                       ------------------------------------------------------------------------------------------
Balance, May 31, 2003                   42,542,500    42,542        35,958             -       (24,312)          -        54,188

Net (loss)                                                 -             -             -       (28,562)          -       (28,562)
                                       ------------------------------------------------------------------------------------------
Balance, May 31, 2004                   42,542,500    42,542        35,958             -       (52,874)          -        25,626

March 2005, stock issued in
  acquisition                           14,300,000     5,600            -              -             -           -         5,600

Reclassification of paid in capital              -     8,700       (8,700)             -             -           -             -

Net (loss)                                       -         -            -              -      (189,993)          -      (189,993)

Foreign currency gain                            -         -            -              -             -       2,117         2,117
                                       ------------------------------------------------------------------------------------------
Balance, May 31, 2005                   56,842,500    56,842       27,258              -      (242,867)      2,117      (156,650)

Private placement shares issued
  for cash at $1.20                        333,333       333      399,667              -             -           -       400,000

Stock issued for research &
  development at $1.22                     450,000       450      368,550       (369,000)            -           -             -

Stock compensation expense                       -         -            -        184,500             -           -       184,500

Net (loss)                                       -         -            -              -      (453,852)          -      (453,852)
                                       ------------------------------------------------------------------------------------------
Balance November 30, 2005               57,625,833  $ 57,625    $ 795,475     $ (184,500)   $ (696,719)    $ 2,117     $ (26,002)
                                       ==========================================================================================
</TABLE>

 The accompanying footnotes are an integral part of these financial statements.


                                      F-4

<PAGE>

                             XPENTION GENETICS, INC.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                                NOVEMBER 30, 2005
                                   (Unaudited)



NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Financial Statements

The accompanying unaudited financial statements of Xpention Genetics,  Inc. have
been prepared in accordance with generally  accepted  accounting  principles for
interim financial  information and with the instructions to Form 10-QSB and Rule
10-01 of  Regulation  S-X.  The  financial  statements  reflect all  adjustments
consisting of normal recurring adjustments, which, in the opinion of management,
are  necessary  for a fair  presentation  of the results for the periods  shown.
Accordingly,  they do not include all of the information and footnotes  required
by generally accepted accounting principles for complete financial statements.

These  financial  statements  should  be read in  conjunction  with the  audited
financial  statements and footnotes  included  thereto for the fiscal year ended
May 31,  2005 for  Xpention  Genetics,  Inc.  on Form  10KSB  as filed  with the
Securities and Exchange Commission.

The preparation of financial  statements in conformity  with generally  accepted
accounting principles requires management to make estimates and assumptions that
affect  the  reported  amounts  of assets  and  liabilities  and  disclosure  of
contingent  assets and  liabilities at the date of the financial  statements and
that effect the reported  amounts of revenues and expenses  during the reporting
period. Actual results could differ from those estimates.

Organization

The Company was incorporated in the State of Nevada,  on September 5, 2002. From
inception  until  February 28, 2005,  the Company was  primarily  engaged in the
acquisition  and  exploration of mining  properties.  Subsequent to February 28,
2005,  the  Company   entered  the   biotechnology   industry  to  develop  both
immunological  and molecular tests for cancer detection in animals and humans as
well as  therapeutic  vaccines and other  treatment  methods for both canine and
human  cancers.  In March  2005,  the  Company  changed  its name  from  Bayview
Corporation to Xpention  Genetics,  Inc. The Company has been in the development
stage since its formation and has not yet realized any revenues from its planned
operations.

Net (Loss) Per Common Share

The Company  follows SFAS 128,  "Earnings Per Share".  Basic earnings (loss) per
common share  calculations  are  determined by dividing net income (loss) by the
weighted average number of shares of common stock  outstanding  during the year.
Diluted earnings (loss) per common share calculations are determined by dividing
net income (loss) by the weighted  average  number of common shares and dilutive
common  share  equivalents  outstanding.   During  the  periods  when  they  are
anti-dilutive,  common  stock  equivalents,  if any, are not  considered  in the
computation.

NOTE 2. COMMITMENTS

On May 31, 2005, the Company  entered into a Research  Agreement with AMC Cancer
Research  Center  for  research  activities  for  the  development  of  the  p65
immunological  test for canines.  The estimated  cost for the project is $58,946
and the agreement expires on January 30, 2006.

On May 28, 2005, the Company  entered into a Research  Contract with  Genethera,
Inc. for research  activities for the development of the p65 molecular assay for
canines.  The contract  became  effective on May 28, 2005 and expires on May 30,
2006 and requires payments to Genethera of $20,000 per month.

                                      F-5

<PAGE>

                             XPENTION GENETICS, INC.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                                NOVEMBER 30, 2005
                                   (Unaudited)


On May 28, 2005,  the Company  entered into a Research  Agreement with Genethera
Inc. for research  activities for the development of the p65 molecular assay for
humans.  The agreement became effective on July 28, 2005 and expires on July 28,
2006 and requires payments to Genethera Inc. of $10,000 per month.

On February 17, 2005,  the  Company's  wholly-owned  subsidiary  Xpention,  Inc.
entered into a License and Technology Licensing Agreement with the University of
Texas  M.D.  Anderson  Cancer  Center  (UTMDACC)  to  commercialize   technology
developed for cancer  detection in animals and humans.  The Company paid $50,000
for the  license  which was  expensed  during the year ended May 31,  2005.  The
Agreement  call for a 5.5% royalty to be paid to UTMDACC on the sale of products
utilizing the licensed technology.  In addition payments of $50,000 each are due
upon the  first  sales to both the  veterinary  market  and  human  market.  The
Agreement expires in February 2020.

On July 21, 2005,  the Company  entered into a Research  Agreement with Colorado
State  University for research  activities in connection with the development of
the p65  immunological  test for canines in which CSU will provide  canine blood
and tissue  specimens for use in clinical  trials.  The agreement  terminates on
July 1, 2006 and requires payments to CSU totaling $17,520.

On November 2, 2005,  the Company  amended its Research  Agreement with Colorado
state  University.  The  amendment  calls for CSU to  collect  additional  blood
samples for use by the Company in development of a canine cancer  detection test
and extends the  agreement  to November 1, 2006.  The Company  will pay Colorado
State  University an additional  $15,330 for the work performed  pursuant to the
amendment.

On June 28,  2005,  the Company  entered into a  Consulting  Agreement  with Dr.
Thomas Slaga for general scientific research assistance. The agreement continues
until at least  May 31,  2006.  The  Company  granted  Slaga  450,000  shares of
restricted common stock as compensation for such services.

On June 15, 2005,  the Company  entered  into a  Subscription  Agreement  with a
private investor for the sale of 333,333 shares of restricted  common stock at a
price of $1.20 per share.

NOTE 3. NOTE PAYABLE

The Company's wholly-owned subsidiary entered into a loan agreement for $100,000
on November 12, 2004.  Interest  accrues at a rate of 5.0% per annum. The note's
original maturity date was November 12, 2005, however, on that date, the parties
agreed to extend the note to March 1, 2006.

NOTE 4. SUBSEQUENT EVENTS

On December 1, 2005,  the company  entered  into a Research  Agreement  with The
University of Texas Health  Science  Center at San Antonio  ("UTHSCSA")  whereby
UTHSCSA  agreed  to  perform   research   activities   for   development  of  an
immunological  test for canines.  This agreement replaces the Research Agreement
the Company  entered into with AMC Cancer  Research Center in May 2005 which has
been  relinquished by AMC. The agreement with UTHSCSA will permit the Company to
continue its  collaboration  with Dr.  Margaret  Hanausek who accepted a faculty
position at UTHSCSA.  The Company will pay $64,306 to UTHSCSA for work performed
pursuant to the Agreement.

                                      F-6

<PAGE>

Item 2. Management's Discussion and Analysis or Plan of Operation

FORWARD LOOKING STATEMENTS

This quarterly report contains forward-looking statements that involve risks and
uncertainties.  We use words such as anticipate,  believe, plan, expect, future,
intend and similar expressions to identify such forward-looking  statements. You
should not place too much  reliance  on these  forward-looking  statements.  Our
actual results are likely to differ  materially from those  anticipated in these
forward-looking  statements  for many  reasons,  including the risks faced by us
described in this Risk Factors section and elsewhere in this annual report.

Plan of Operation

The Company, through its wholly-owned subsidiary,  holds the exclusive worldwide
license for  patented  technology  for the  detection of cancer based on a tumor
marker known as p65 which has been  demonstrated  to have elevated levels in the
blood of canine and human  cancer  conditions.  p65 is  believed to be a protein
required in the early  development  of numerous  cancers and appears  from early
research  to provide a strong  indication  of tumor  growth in both  canines and
humans.  It also appears to have a direct  correlation to tumor size/mass making
it a promising  marker for both early  detection of malignant tumor formation as
well as a useful tool for  monitoring  therapy  and  remission.  Initially,  the
Company plans to develop an immunological  test as well as a molecular assay for
detection  of  cancer  in  canines.  The  Company  also  plans to  develop  both
immunological  and  molecular  tests for  detection of human  cancers as well as
therapeutic treatments and vaccines.

During the interim  period ended  November 30, 2005,  the Company  continued its
research  activities  for the  development  of an  immunological  canine  cancer
detection  test as well as a  molecular  assay for  detection  of cancer in both
canines and humans,  all of which are being conducted by third parties on behalf
of the company.  In November  2005, the Company  amended its Research  Agreement
with Colorado State University in which CSU will, in addition to providing blood
and tissue samples for use in the development of the immunological canine cancer
detection  test,  also provide blood samples to be used in the  development of a
molecular  cancer  detection  test for canines.  The Company  also  continues to
evaluate various options for  commercialization of its products;  however, it is
not   anticipated   that  the  Company   will   generate   any   revenues   from
commercialization of its products during FY 2006.

Results of Operations for the Quarter Ended November 30, 2005

The Company did not earn any revenues  during the quarter period ending November
30, 2005.  For the  three-month  period  ending  November 30, 2005,  the Company
incurred expenses totaling $225,743 including research and development  expenses
of  $102,665,   administrative   expenses  of  $30,828  and  stock  compensation
(non-cash) of $92,250.  During the three-month  period ending November 30, 2004,
the  Company  was  still  involved  in  mineral  exploration  and only  incurred
administrative expenses of $2864 and mineral option payments totaling $2000.

<PAGE>

The Company had a net loss for the quarter of  ($226,993) in the quarter in 2005
compared to  ($4,864) in the quarter in 2004.  Net loss per share was nominal in
the quarters in 2005 and 2004.

RESULTS OF OPERATIONS FOR THE SIX-MONTH PERIOD ENDED NOVEMBER 30, 2005

The Company had no revenues in the six-month period.

For the six-month period ending November 30, 2005, the Company incurred expenses
totaling  $451,352  including  research  and  development  expenses of $181,425,
administrative   expenses  of  $85,427  and  stock  compensation  (non-cash)  of
$184,500.  For the same six-month  period ending  November 30, 2004, the Company
incurred  expenses  totaling  $5,860 in the form of general  and  administrative
expenses and mineral option payments.

The Company  expects the trend of losses,  in the future,  will  continue at the
current rate until revenues can be achieved, which is not assured.

The Company  had  $178,709  in cash on hand at  November  30, 2005 and  accounts
payable and accrued liabilities totaling $104,711 and note a payable of $100,000
at November 30, 2005.

The Company issued 333,333 shares of stock at a price of $1.20 per share in June
2005  generating  $400,000  in cash,  the  proceeds  of which were used to cover
research  and  development  expenses as well as  administrative  expenses of the
Company during the period.

The Company has no capital  resources other than its capital stock with which to
raise more cash.

Item 3.  Controls and Procedures

Within 90 days prior to the date of this Form 10-QSB, the Company carried out an
evaluation,  under the supervision and with the  participation  of the Company's
President and Chief Financial  Officer,  of the  effectiveness of the design and
operation of the Company's  disclosure  controls and procedures (as such term is
defined in Rules  13a-14(c) and 15d-14(c)  under the Securities  Exchange Act of
1934, as amended (the "Exchange Act"). Based upon such evaluation, such officers
have  concluded  that the  Company's  disclosure  controls  and  procedures  are
effective in alerting them, on a timely basis, to material  information relating
the Company required to be included in this Form 10-QSB.

There have been no significant  changes to the Company's  internal controls over
financial reporting that have materially  affected,  or are reasonably likely to
materially effect, the Company's internal controls over financial reporting.


<PAGE>



                           PART II - OTHER INFORMATION

Item 1.  Legal Proceedings

The Company is not a party to any pending legal proceeding.  Current  management
is not aware of any threatened litigation, claims or assessments.


Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds

The Company did not issue any  securities  during the quarter ended November 30,
2005.


Item 3. Defaults Upon Senior Securities

         None.


Item 4. Submission of Matters to a Vote of Security Holders

         None.


Item 5. Other Information

         None.


Item 6. Exhibits

31    Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant
      to Section 302 of the Sarbanes-Oxley Act of 2002

32    Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant
      to Section 906 of the Sarbanes-Oxley Act of 2002

<PAGE>

                                   SIGNATURES

In accordance with the  requirements of the Exchange Act, the registrant  caused
this  report to be  signed on its  behalf  by the  undersigned,  thereunto  duly
authorized.

Dated:  January 23, 2006

                                        Xpention Genetics, Inc.

                                        /s/ David Kittrell
                                        ------------------------------
                                        David Kittrell, President